Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigamabs
- Development stage
- Phase 2
- Lead developer
- Thallion Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Shigamabs is a combination of two chimeric monoclonal antibodies, cαStx1 and cαStx2, designed to neutralize Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2), respectively. These toxins are produced by Shiga toxin-producing Escherichia coli (STEC) and are the primary drivers of Hemolytic Uremic Syndrome (HUS), a severe condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. By binding to and neutralizing the toxins in the systemic circulation, Shigamabs aims to prevent the toxins from entering host cells and causing the vascular damage that leads to HUS. The drug was developed by Thallion Pharmaceuticals and was evaluated in the Phase II SHIGATEC trial in pediatric patients with STEC infections. However, the development program was terminated following the acquisition of Thallion by Bellus Health.
- Brand names
- Shigamabs
- Other names
- Shigamabs
02
Targets
Stx2 (Shiga toxin 2)Stx1 (Shiga toxin 1)
Beyond the preview
Go deeper on Shigamabs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigamabs.